Revolutionizing Cannabis Edibles: Ascend's New THC-Cannabinoid Blends Now Available In This East Coast Market

Vertically integrated cannabis operator Ascend Wellness Holdings (CSE:AAWH) (OTCQX:AAWH) announced the launch on Thursday of its new edibles-only brand, Effin’.

The New Jersey-based company said Effin’ focuses on delivering specific effects through expertly formulated combinations of THC and minor cannabinoids like THCV, CBN, CBG and CBD.

• Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.

Effin’ initially debuted in Massachusetts and Illinois in early October, with a New Jersey launch planned for the end of the month.

The four initial SKUs include:

• Effin’ Chillin’ with 10 mg THC to 10 mg CBD;
• Effin’ Sleep featuring 10 mg THC to 5 mg CBN;
• Effin’ Hang with 20 mg CBG to 10 mg THC; and
• Effin’ Do It features 10 mg THC to 10 mg THCV.

“We went mad scientist to create these unique formulations because we know our customers want more than just edibles—they want products that deliver specific effects tailored to their needs,” said David Gacom, chief commercial officer at AWH.

Ascend is slated to hold a conference call on Tuesday, Nov. 12, 2024, at 8:30 am ET following the release of its third quarter 2024 financial results.  

The New York-headquartered company closed its previously announced private placement of $235 million of 12.75% senior secured notes due 2029 in July with plans to prepay $215 million of principal amounts outstanding under its existing term loan.

AAWH Price Action

Ascend's shares traded 3.21% higher at $0.7947 per share at the time of writing on Thursday.